CRISPR Base Editing Confirms 97% Sickle Cell Cure Rate

The FDA approved Casgevy (exa-cel) for sickle cell disease in 2023, but the true scientific milestone arrived in 2025 when 2-year follow-up data confirmed 97% of treated patients were free of vaso-occlusive crises — the debilitating pain events that define the disease. More significantly, a next-generation base editing therapy (BE3.9) published in NEJM achieved the same outcome through a more precise mechanism with 60% lower off-target editing events compared to Casgevy. Base editing changes individual nucleotides without creating double-strand DNA breaks, dramatically reducing unintended edits. The manufacturing cost per patient dropped from $2.2 million at initial approval to $890,000 by end of 2025 due to process optimization — still prohibitive without insurance, but on a cost reduction trajectory that suggests eventual broader access. This is the field most biologists point to as proof that gene editing has moved from laboratory tool to clinical medicine.